ArticleImmunology and cell biology2026
The N6-Methyladenosine-Modified CIT Promotes Uterine Corpus Endometrial Carcinoma Progression by Inhibiting the Hippo Signaling Pathway.
Article in Immunology and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigates the role of CIT gene in uterine corpus endometrial carcinoma (UCEC) progression, focusing on its regulation by m6A methylation. Bioinformatics and experimental analyses (EdU, colony formation assay, Dot blot, MeRIP-PCR, RNA pull-down, qRT-PCR, Western Blotting, apoptosis assay) revealed that CIT was significantly overexpressed in UCEC. Mechanistically, we found that the m6A writer RBM15-mediated CIT mRNA methylation, which was then recognized by the reader IGF2BP1 to enhance CIT mRNA stability and expression. Consequently, this m6A-mediated upregulation of CIT inhibited the Hippo signaling pathway, ultimately suppressing apoptosis and promoting malignant proliferation in UCEC. These findings elucidated a novel RBM15/IGF2BP1-CIT-Hippo axis, providing new theoretical insights and potential therapeutic targets for UCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.